Difference between revisions of "Template:Article of the week"

From LIMSWiki
Jump to navigationJump to search
(Updated article of the week text)
(19 intermediate revisions by the same user not shown)
Line 1: Line 1:
<div style="float: left; margin: 0.5em 0.9em 0.4em 0em;">[[File:Tab2 Valdes-Donoso CaliforniaAg2019 73-3.jpg|240px]]</div>
<div style="float: left; margin: 0.5em 0.9em 0.4em 0em;">[[File:Anx1 WHO 2020 2020.5.png|240px]]</div>
'''"[[Journal:Costs of mandatory cannabis testing in California|Costs of mandatory cannabis testing in California]]"'''
'''"[[Journal:Laboratory testing for coronavirus disease (COVID-19) in suspected human cases|Laboratory testing for coronavirus disease (COVID-19) in suspected human cases]]"'''


Every batch of [[wikipedia:Cannabis|cannabis]] sold legally in California must be tested for more than 100 contaminants. These contaminants include 66 pesticides, for 21 of which the state's tolerance is zero. For many other substances, tolerance levels are much lower than those allowed for food products in California. This article reviews the state's testing [[Regulatory compliance|regulations]] in context—including maximum allowable tolerance levels—and uses primary data collected from California's major cannabis testing [[Laboratory|laboratories]] and several cannabis testing equipment manufacturers, as well as a variety of expert opinions, to estimate the cost per pound of testing under the state's framework. We also estimate the cost of collecting [[Sample (material)|samples]], which depends on the distance between cannabis distributors and laboratories. We find that, if a batch fails mandatory tests, the value of cannabis that must be destroyed accounts for a large share of total testing costs, more than the cost of the tests that laboratories perform. Findings from this article will help readers understand the effects of California's testing regime on the price of legal cannabis in the state, and understand how testing may add value to products that have passed a series of tests that aim to validate their safety. ('''[[Journal:Costs of mandatory cannabis testing in California|Full article...]]''')<br />
This document provides interim guidance to [[Laboratory|laboratories]] and stakeholders involved in [[COVID-19]] virus laboratory testing of patients. It is based in part on the interim guidance on laboratory testing for [[Middle East respiratory syndrome]] (MERS) coronavirus. [[Information]] on human [[infection]] with the COVID-19 virus is evolving and the [[World Health Organization]] (WHO) continues to monitor developments and revise recommendations as necessary. This document will be revised as new information becomes available. Feedback is welcome and can be sent to WHElab@who.int. The virus has now been named SARS-CoV-2 by the International Committee of Taxonomy of Viruses (ICTV)(2). This virus can cause the disease named coronavirus disease 2019 (COVID-19). WHO refers to the virus as COVID-19 virus in its current documentation. ('''[[Journal:A security review of local government using NIST CSF: A case study|Full article...]]''')<br />
<br />
<br />
''Recently featured'':
''Recently featured'':
: ▪ [[Journal:An integrated data analytics platform|An integrated data analytics platform]]
: ▪ [[Journal:One tool to find them all: A case of data integration and querying in a distributed LIMS platform|One tool to find them all: A case of data integration and querying in a distributed LIMS platform]]
: ▪ [[Journal:Virtualization-based security techniques on mobile cloud computing: Research gaps and challenges|Virtualization-based security techniques on mobile cloud computing: Research gaps and challenges]]
: ▪ [[Journal:What is the "source" of open-source hardware?|What is the "source" of open-source hardware?]]
: ▪ [[Journal:Building open access to research (OAR) data infrastructure at NIST|Building open access to research (OAR) data infrastructure at NIST]]
: ▪ [[Journal:From command-line bioinformatics to bioGUI|From command-line bioinformatics to bioGUI]]

Revision as of 15:46, 23 March 2020

Anx1 WHO 2020 2020.5.png

"Laboratory testing for coronavirus disease (COVID-19) in suspected human cases"

This document provides interim guidance to laboratories and stakeholders involved in COVID-19 virus laboratory testing of patients. It is based in part on the interim guidance on laboratory testing for Middle East respiratory syndrome (MERS) coronavirus. Information on human infection with the COVID-19 virus is evolving and the World Health Organization (WHO) continues to monitor developments and revise recommendations as necessary. This document will be revised as new information becomes available. Feedback is welcome and can be sent to WHElab@who.int. The virus has now been named SARS-CoV-2 by the International Committee of Taxonomy of Viruses (ICTV)(2). This virus can cause the disease named coronavirus disease 2019 (COVID-19). WHO refers to the virus as COVID-19 virus in its current documentation. (Full article...)

Recently featured:

▪ One tool to find them all: A case of data integration and querying in a distributed LIMS platform
▪ What is the "source" of open-source hardware?
▪ From command-line bioinformatics to bioGUI
Retrieved from "https://www.limswiki.org/index.php?title=Template:Article_of_the_week&oldid=38742"